#VisualAbstract: Treatment of metastatic uveal melanoma with tebentafusp compared to standard treatment
1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse ...
1. Median overall survival and progression-free survival were greater in the tebentafusp group compared to the control group. 2. Adverse ...
1 .Tumor-infiltrating lymphocytes therapy shows improvements in PFS when compared to ipilimumab 2. All patients with tumor-infiltrating lymphocytes therapy had ...
Click to read this study in the Journal of Clinical Oncology.
Click to read the study in the Journal of Investigative Dermatology.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
Click to read the study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
Click to read the study in the European Journal of Cancer.
Click to read the study in JAMA Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.